butyl N-[1-[5-azido-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxopyrimidin-4-yl]carbamate

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: butyl N-[1-[5-azido-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxopyrimidin-4-yl]carbamate
• 化学式: C14H20N6O7
• 分子量: 384.34
• InChiKey: MCUGBMHLCZXTCY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  27
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  155
• 氢给体数：
  4
• 氢受体数：
  9

文献信息

• Antiviral nucleoside derivatives
  申请人：Roche Palo Alto LLC

  公开号：US20040121980A1

  公开（公告）日：2004-06-24

  The present invention relates to nucleoside derivatives for the treatment of Hepatitis C viral infections including compounds of formula I, pharmaceutical compositions comprising these compounds and methods for treatment or prophylaxis of Hepatitis C Virus mediated diseases employing said compounds in monotherapy or in combination therapy. The present invention further provides a process for preparing 1′,3′,4′-triacyl pyrimidine nucleoside from a N, 1′,3′,4′-tetraacylpyrimidine nucleoside 1

  本发明涉及用于治疗丙型肝炎病毒感染的核苷酸衍生物，包括式I的化合物，以及包含这些化合物的制药组合物和使用这些化合物进行单一治疗或联合治疗的预防或治疗丙型肝炎病毒介导疾病的方法。本发明还提供了一种从N，1′，3′，4′-四酰基嘧啶核苷酸制备1′，3′，4′-三酰基嘧啶核苷酸的方法。
• US6846810B2
  申请人：——

  公开号：US6846810B2

  公开（公告）日：2005-01-25
• [EN] CONCENTRATED OXALIPLATIN SOLUTIONS<br/>[FR] SOLUTIONS CONCENTREES D'OXALIPLATINE
  申请人：MAYNE PHARMA PTY LTD

  公开号：WO2005102312A1

  公开（公告）日：2005-11-03

  There is provided a pharmaceutical liquid formulation for parental administration comprising: (a) greater than 5 mg/mL oxaliplatin; (b) water; and (c) at least an effective solubilising amount of a cyclodextrin. The invention further provides use of a pharmaceutical formulation in the treatment of cancer and a method for treating cancer in a patient which comprises administrating a therapeutic amount of a pharmaceutical formulation. A method for preparing a pharmaceutical liquid formulation of oxaliplatin is also disclosed.